gopubmed logo
 
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 24 Oct 2014.

Interleukin 6 receptor

IL-6R, interleukin-6 receptor, gp80, IL-6Ralpha
This gene encodes a subunit of the interleukin 6 (IL6) receptor complex. Interleukin 6 is a potent pleiotropic cytokine that regulates cell growth and differentiation and plays an important role in the immune response. The IL6 receptor is a protein complex consisting of this protein and interleukin 6 signal transducer (IL6ST/GP130/IL6-beta), a receptor subunit also shared by many other cytokines. Dysregulated production of IL6 and this receptor are implicated in the pathogenesis of many diseases, such as multiple myeloma, autoimmune diseases and prostate cancer. Alternatively spliced transcript variants encoding distinct isoforms have been reported. A pseudogene of this gene is found on chromosome 9.[provided by RefSeq, May 2011] (from NCBI)
Top mentioned proteins: Interleukin-6, NMDA receptor, CAN, V1a, STAT3
Papers using IL-6R antibodies
Peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, protects against nephropathy and pancreatic islet abnormalities in Zucker fatty rats.
Supplier
Sesti Giorgio, In PLoS ONE, 1997
... used anti-cytokines antibodies against IL-1ß, IL-6, TNFα, IFNγ, and anti-cytokine receptor antibodies against IL-1R1, IL-1R2, IL-6R, TNF-R1, IFN-Rα, IFN-Rß (Santa Cruz Biotechnology, Santa Cruz, CA); guinea ...
Papers on IL-6R
Regulatory B cells are induced by gut microbiota-driven interleukin-1β and interleukin-6 production.
New
Impact
Mauri et al., Udine, Italy. In Nat Med, 19 Nov 2014
Mice lacking IL-6 receptor (IL-6R) or IL-1 receptor 1 (IL-1R1) specifically on B cells have a reduced number of IL-10-producing B cells and develop exacerbated arthritis compared to control animals.
Financial strain, inflammatory factors, and haemoglobin A1c levels in African American women.
New
Philibert et al., Ames, United States. In Br J Health Psychol, 18 Nov 2014
METHODS: We assessed level of financial strain four times over a 10-year period and tested its effect on two serum inflammation markers, C-reactive protein (CRP) and soluble interleukin-6 receptor (sIL-6R) in year 11 of the study.
Chimeric antigen receptor T cells for sustained remissions in leukemia.
New
Impact
Grupp et al., Australia. In N Engl J Med, 16 Nov 2014
Severe cytokine-release syndrome, which developed in 27% of the patients, was associated with a higher disease burden before infusion and was effectively treated with the anti-interleukin-6 receptor antibody tocilizumab.
Predictive model for risk of severe gastrointestinal toxicity following chemotherapy using patient immune genetics and type of cancer: a pilot study.
New
Bowen et al., Adelaide, Australia. In Support Care Cancer, 16 Nov 2014
METHODS: Genomic DNA from 34 patients (10 with severe CIGT) who had received 5-fluoruracil-based chemotherapy regimens was analyzed for variants of IL-1B, IL-2, IL-6, IL-6R, IL-10, TNF-a, TGF-b, TLR2, TLR4, MD2, MYD88, BDNF, CRP, ICE, and OPRM1.
Role of interleukin-6 in cachexia: therapeutic implications.
New
Carson et al., Columbia, United States. In Curr Opin Support Palliat Care, 14 Nov 2014
IL-6 trans-signaling through the soluble IL-6R has the potential to amplify IL-6 signaling in the cachectic patient.
Anti-Interleukin 6 Receptor Antibodies Attenuate Antibody Recall Responses in a Mouse Model of Allosensitization.
New
Jordan et al., Los Angeles, United States. In Transplantation, 03 Nov 2014
The current study evaluated the effect of IL-6 receptor (IL-6R) blockade with an anti-IL-6R monoclonal (mMR16-1) in alloantibody recall responses.
[Use of Tocilizumab, an Antibody against Interleukin-6 Receptor, for the Treatment of Neuromyelitis Optica].
New
Araki et al., In Brain Nerve, 31 Oct 2014
Abstract Our lab has previously shown that Interleukin (IL)-6- dependent production of autoantibodies against aquaporin 4 in plasmablasts may play a central role in the pathogenesis of neuromyelitis optica (NMO).
ADAM17 at the interface between inflammation and autoimmunity.
Review
New
Sisto et al., Bari, Italy. In Immunol Lett, 26 Sep 2014
IL-6R and TNF-R), ligands of ErbB (e.g.
Therapeutic uses of anti-interleukin-6 receptor antibody.
Review
New
Kishimoto et al., Suita, Japan. In Int Immunol, 20 Sep 2014
UNLABELLED: Cytokine-targeted therapy has generated a paradigm shift in the treatment of several immune-mediated diseases.
Interleukin-6 in renal disease and therapy.
Review
New
Jones et al., Cardiff, United Kingdom. In Nephrol Dial Transplant, Aug 2014
Here, drugs including the humanized anti-IL-6 receptor (IL-6R) antibody tocilizumab emphasize the clinical importance of IL-6 in driving disease and poor patient outcomes.
Interleukin-6 and its receptors: A highly regulated and dynamic system.
Review
New
Garbers et al., Kiel, Germany. In Cytokine, Jul 2014
IL-6 induces intracellular signaling pathways after binding to its membrane-bound receptor (IL-6R), which is only expressed on hepatocytes and certain subpopulations of leukocytes (classic signaling).
Role of the interleukin 6 receptor family in epithelial ovarian cancer and its clinical implications.
Review
New
Ward et al., Geelong, Australia. In Biochim Biophys Acta, Apr 2014
In particular, members of the IL-6R family acting via the downstream STAT3 transcription factor play an important role in a number of solid tumors - including ovarian cancer - by altering the expression of target genes that impact on key phenotypes.
Metalloproteinases and their natural inhibitors in inflammation and immunity.
Review
New
Impact
Weiss et al., Toronto, Canada. In Nat Rev Immunol, Sep 2013
Together with their endogenous inhibitors TIMPs (tissue inhibitor of metalloproteinases), these enzymes regulate signalling downstream of the tumour necrosis factor receptor and the interleukin-6 receptor, as well as that downstream of the epidermal growth factor receptor and Notch, which are all pertinent for inflammatory responses.
Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis.
Impact
PRCSG et al., Roma, Italy. In N Engl J Med, 2013
METHODS: We randomly assigned 112 children, 2 to 17 years of age, with active systemic JIA (duration of ≥6 months and inadequate responses to nonsteroidal antiinflammatory drugs and glucocorticoids) to the anti-interleukin-6 receptor antibody tocilizumab (at a dose of 8 mg per kilogram of body weight if the weight was ≥30 kg or 12 mg per kilogram if the weight was <30 kg) or placebo given intravenously every 2 weeks during the 12-week, double-blind phase.
The IL6R variation Asp(358)Ala is a potential modifier of lung function in subjects with asthma.
GeneRIF
National Heart et al., Winston-Salem, United States. In J Allergy Clin Immunol, 2012
The IL6R coding SNP rs2228145 (Asp358Ala) is a potential modifier of lung function in subjects with asthma and might identify subjects at risk for more severe asthma.
Blockade of interleukin-6 receptor suppresses the proliferation of H460 lung cancer stem cells.
GeneRIF
Shin et al., South Korea. In Int J Oncol, 2012
IL-6R is present in cancer stem cells and has an important role in the proliferation
Interleukin-6 receptor α is co-localised with melanin-concentrating hormone in human and mouse hypothalamus.
GeneRIF
Jansson et al., Göteborg, Sweden. In J Neuroendocrinol, 2012
Il6r alpha is co-localized with melanin-concentrating hormone in mouse hypothalamus.
Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies.
Impact
GeneRIF
Danesh et al., In Lancet, 2012
We assessed Asp358Ala in relation to localised gene expression and to postlipopolysaccharide stimulation of interleukin 6.
The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis.
Impact
Casas et al., In Lancet, 2012
Blockade of the interleukin-6 receptor (IL6R) with a monoclonal antibody (tocilizumab) licensed for treatment of rheumatoid arthritis reduces systemic and articular inflammation.
Elevated urinary sVCAM-1, IL6, sIL6R and TNFR1 concentrations indicate acute kidney transplant rejection in the first 2 weeks after transplantation.
GeneRIF
Banas et al., Regensburg, Germany. In Cytokine, 2012
Elevated urinary concentrations of IL6, sIL6R, TNFR1 and sVCAM-1 clearly indicate an early acute transplant rejection.
share on facebooktweetadd +1mail to friends